Safety and Efficacy of AT-001 in Patients With Diabetic Cardiomyopathy
A phase 3 trial registered on ClinicalTrials.gov. The registry status is active, not recruiting. It plans to enroll 675 participants.
Also called NCT04083339
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 675 participants
- Sponsor
- Applied Therapeutics, Inc.
- Registry
-
NCT04083339
-
- Other papers using this trial's data
- Echocardiographic phenotypes of diabetic myocardial disorder: evolution over 15 months follow-up in the ARISE-HF trial
- Impaired Exercise Capacity in High-Risk Diabetic Cardiomyopathy: The ARISE-HF Cardiopulmonary Exercise Testing Subanalysis
- Racial outcomes in patients with diabetic cardiomyopathy treated with an aldose reductase inhibitor: the ARISE-HF trial
- Randomized Trial of a Selective Aldose Reductase Inhibitor in Patients With Diabetic Cardiomyopathy
- Relationship between NT-proBNP, echocardiographic abnormalities and functional status in patients with subclinical siabetic cardiomyopathy
- Sex Differences in Diabetic Cardiomyopathy and Treatment Response to AT-001: Insights From the ARISE-HF Study
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- United States, Australia, Canada, Czechia, France, Germany, Hong Kong SAR China, Poland, Spain, United Kingdom
- Registry status
- Active, not recruiting
Technical summary
Registry record NCT04083339. Randomized; quadruple masking; primary purpose treatment. Start 2019-09-20 (actual); primary completion 2023-12 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Safety and Efficacy of AT-001 in Patients With Diabetic Cardiomyopathy
- Condition
- Diabetic Cardiomyopathies
- Intervention (Drug)
- AT-001
- Intervention (Drug)
- Placebo
- Lead sponsor
- Applied Therapeutics, Inc.
Record details
- Record id
cardio:ct-nct04083339- Content hash
fafc79562770244b00d282f811ce896ed60ce61c3c2c842f6b088675d64592f4